Department of Medical Oncology - Università Politecnica delle Marche, Ancona, Italy
Luca Faloppi , Mario Scartozzi , Marco D'Anzeo , Maristella Bianconi , Gianluca Svegliati Baroni , Nicola Silvestris , Andrea Casadei Gardini , Gianluca Masi , Riccardo Giampieri , Michela Del Prete , Samuele De Minicis , Alessandra Mandolesi , Antonio Benedetti , Stefano Cascinu
Background: Tumour cells adapt to hypoxic microenvironment via the activation of numerous molecules, among which hypoxia inducible factor 1 (HIF-1) is the most important. HIF-1 plays a crucial role in tumour angiogenesis triggering the transcription of several genes including the vascular endothelial growth factor (VEGF). Currently the therapeutic stronghold of advanced hepatocellular carcinoma (HCC) is the antiangiogenetic TKIs sorafenib. The overexpression of HIF-1 in HCC is associated with tumour angiogenesis, invasion, metastasis, treatment resistance and poor prognosis. In our previous report polymorphisms (SNPs) CC+CG>GG of rs2010963 and TT+CT>CC rs4604006 of VEGF have been shown to predict clinical outcome in HCC patients treated with sorafenib. Methods: From a large database a preliminary analysis on 90 HCC patients receiving sorafenib was conducted to assess the role of HIF-1 SNPs in determining the clinical outcome in this setting. Tumour histologic samples were tested for 8 different HIF-1 SNPs. Patients progression free survival (PFS) and overall survival (OS) were analysed. Results: At univariate analysis CC>AA+AC of rs1951795, TT>CC+CT of rs10873142, AA+AG>GG of rs12434438 SNPs were statistically significant for PFS and OS. At multivariate analysis rs1951795 of HIF-1, rs2010963 of VEGF-A and rs4604006 of VEGF-C have been confirmed as independent factors (Table). Conclusions: This investigation on HIF-1 SNPs, following our previous discoveries on VEGF and its receptors, may represent a clinical tool to identify patients with favourable response to sorafenib, presumably related to a more efficient control of tumour growth.
Genotype | Univariate analysis |
Multivariate analysis |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
SNPs |
PFS |
OS |
p | PFS |
OS |
|||||||
mo | p | mo | p | mo | p | HR | IC | HR | IC | |||
HIF-1a | rs1951795 | CC | 6.8 | 0.0271 | 16.1 | 0.0174 | 0.0332 | 0.33 | 0.12-0.91 | 0.0182 | 0.20 | 0.10-0.76 |
AA+AC | 3.0 | 12.6 | ||||||||||
rs10873142 | TT | 6.7 | 0.0427 | 16.0 | 0.0247 | ns | ns | |||||
CC+TT | 3.4 | 12.7 | ||||||||||
rs12434438 | AA+AG | 6.1 | 0.0181 | 14.7 | 0.0225 | ns | ns | |||||
GG | 2.6 | 10.6 | ||||||||||
VEGF-A | rs2010963 | CC+CG | 6.9 | 0.0096 | 17.0 | 0.0016 | 0.0279 | 0.63 | 0.37-1.05 | 0.0248 | 0.50 | 0.28-0.91 |
GG | 4.0 | 9.0 | ||||||||||
VEGF-C | rs4604006 | TT+TC | 10.1 | 0.0043 | 22.0 | 0.0334 | 0.0022 | 0.42 | 0.24-0.73 | 0.0335 | 0.50 | 0.27-0.94 |
CC | 4.3 | 13.0 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Laura A. Dawson
2022 ASCO Annual Meeting
First Author: Julien Edeline
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Julien Edeline
2021 Gastrointestinal Cancers Symposium
First Author: Timothy J Brown